Across 114 CTIS-authorized dermatology Phase III trials in Europe, CRO or outsourced provider support appeared in 82 trials, equal to 71.9% of the cohort. CRO need was strongest in operationally larger studies: 59 of 61 trials with at least 5 countries used CRO support, and all 10 trials with at least 600 participants used CRO support. ICON was the most active traditional CRO, followed by IQVIA, PPD / Thermo Fisher, Syneos Health, and Parexel.
Among 114 dermatology Phase III trials, ICON supported 31 trials, IQVIA supported 22, PPD / Thermo Fisher supported 16, Syneos Health supported 14, and Parexel supported 11. Overall, 82 of 114 trials had at least one CRO or outsourced provider listed.
The CRO market is concentrated but not closed: the top five traditional CROs account for the strongest repeated presence, while many trials also list specialized service providers for technology, lab, logistics, recruitment, and patient support.
CRO support was present in 59 of 61 trials with at least 5 countries, equal to 96.7%. CRO use also reached 25 of 26 trials with at least 50 sites and 31 of 35 trials with at least 300 participants.
The practical CRO threshold in European dermatology Phase III trials is not simply “large sample size.” CRO dependency appears once a study becomes multi-country and CTIS Part II coordination, site activation, recruitment materials, translation, patient support, and vendor oversight scale across jurisdictions.
By indication group, CRO support appeared in 18 of 20 psoriasis or psoriatic-disease trials, 15 of 18 atopic dermatitis or eczema trials, 11 of 11 hidradenitis suppurativa trials, and 7 of 7 chronic spontaneous urticaria trials.
CRO demand is highest in competitive inflammatory dermatology indications where large multi-country patient recruitment, repeated efficacy assessments, patient-reported outcomes, and country-specific CTIS submission workflows create operational intensity.
Across 114 trials, laboratory / biomarker / PK testing appeared in 45 trials, patient recruitment / retention / reimbursement in 39 trials, investigational medicinal product logistics in 39 trials, study operations / CRO management in 38 trials, and digital systems such as eCOA, eDiary, EDC, IRT, or data repositories in 37 trials.
Dermatology outsourcing is not only full-service CRO work. The strongest recurring needs are specialized operational modules: central labs, biomarker or PK handling, IMP supply, reimbursement, recruitment channels, and digital endpoint / trial-management infrastructure.
CRO-supported trials had a median of 6 countries versus 1 country in trials without CRO support. Median country-level CTIS Part II processing time was 207.3 days in CRO-supported trials versus 92.5 days in trials without CRO support, reflecting the higher regulatory and country-activation load of outsourced studies.
The CTIS signal supports a practical buying trigger: when dermatology Phase III trials expand across multiple EU/EEA countries, sponsors increasingly need CROs for country submissions, local documents, recruitment materials, site readiness, and ongoing authorization management.
Digital recruitment trials used CRO support in 42 of 44 cases. Adaptive trials used CRO support in 12 of 12 cases, pediatric trials in 37 of 45 cases, monoclonal-antibody trials in 35 of 40 cases, and small-molecule trials in 46 of 67 cases.
The adjacent data suggest that CRO demand is highest when dermatology trials combine EU submission complexity with patient-facing recruitment, pediatric consent / assent operations, biologic or immunology-adjacent products, and non-standard operational designs.
CRO means contract research organization. CTIS means Clinical Trials Information System. EU/EEA country coordination refers to country-level trial authorization work in the CTIS environment. IMP means investigational medicinal product. PK means pharmacokinetics. eCOA means electronic clinical outcome assessment. EDC means electronic data capture. IRT means interactive response technology.